Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
After a year, the people taking tirzepatide were: Nearly twice as likely to lose 5% of their body weight
The human brain due to the high oxygen consumption is extremely susceptible to the generation of reactive oxygen species
Semaglutide, with its fatty acid chain at position 26, is particularly susceptible to mechanical denaturation
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
The thyroid thing was a theoretical concern based on rodent research
Among the cohort, 49% were prescribed dulaglutide (Trulicity, Eli Lilly) in 2020, which was the most prescribed GLP-1 receptor agonist during the study, according to researchers
